⚡ 5-Minute Revision Dashboard

<aside> 🧠

The organising truth A red-cell unit is not the treatment. The treatment is a purposeful, longitudinal transfusion programme: define phenotype and objective, prescribe the regimen, select a safe component, then repeatedly test whether benefit still outweighs burden. [1, pp. 4–25, 30–34, 38–43]

</aside>

Your five-minute route

Minute Question High-yield answer
1 Why transfuse now? Start with steady-state phenotype, symptoms, growth, ineffective erythropoiesis and complications, not genotype or one Hb value alone.
2 Which lane? TDT is usually sustained support; NTDT is commonly episodic or goal-directed; alpha-thalassaemia needs functional-haemoglobin-aware individualisation.
3 What is prescribed? Write target, interval, dose or units, rate, monitoring and the clinical outcome expected. An interval copied forward is not a prescription.
4 What makes the unit safe? Protect the complete antibody and reaction history; match deliberately; use component modification only for a documented indication.
5 What has changed? Review benefit, pre-transfusion Hb trend, symptoms, reactions, alloimmunisation, iron, spleen, burden and whether the original indication remains valid.

<aside> 🩺

DECIDE BY PHENOTYPE For suspected TDT, a regular programme follows repeated evidence of disease burden. A transient infectious fall or one top-up transfusion must not silently become lifelong treatment. [1, pp. 5–6]

</aside>

<aside> 🎯

PRESCRIBE THE WHOLE REGIMEN For most TDT, the usual pre-transfusion target is 9.5–10.5 g/dL, generally every 2–5 weeks. A 10–11 g/dL target may be appropriate in selected settings. [1, pp. 7–10]

</aside>

<aside> 🧬

PREVENT AVOIDABLE HARM Before regular donor exposure, obtain extended red-cell phenotype or genotype where possible; preserve every historical alloantibody even if the current screen is negative. [1, pp. 6–7, 17–19]

</aside>

Compare the phenotype lanes

<aside> 🩸

TDT Regular, long-term support to sustain function and suppress ineffective erythropoiesis.

Trap: do not reduce initiation to genotype or one Hb result.

</aside>

<aside> ⏱️

NTDT Acute, episodic or time-limited support for a defined clinical aim; regular support only after individual appraisal.

Trap: do not let a goal-directed programme continue by inertia.

</aside>

<aside> 🧬

ALPHA-THALASSAEMIA / HbH On-demand or individualised regular support, guided by phenotype and effective Hb where relevant.

Trap: total Hb can overstate useful oxygen carriage.

</aside>

<aside> 🛡️

The pre-issue safety card

<aside> ⚠️

Four revision traps

  1. A number is not an indication: separate baseline disease from reversible or intercurrent illness.
  2. “Fresh” is not enough: appropriate antigen matching is preventive care.
  3. Every unit has a cost: track iron, interval, cumulative use, chelation, organ assessment and practical burden.
  4. Dependence can change: NTDT and alpha-thalassaemia programmes require reassessment, not inertia. [1, pp. 5–6, 17–18, 20–22, 31–34, 40–43] </aside>

Twenty-second flashcards

<aside> 🧭

Use safely: this dashboard is a rapid revision and MDT-navigation aid, not an autonomous prescription. Local blood-bank policy, component availability, haemovigilance requirements and patient-specific specialist judgement remain controlling.

</aside>

🩸 Blood Transfusion in the Thalassaemia Syndromes — TIF 2025 — Deep Wiki

<aside> 📚

Source read and bibliographic record This Deep Wiki is grounded in the complete 45-page TIF Topics in Focus booklet, Blood Transfusion in the Thalassaemia Syndromes (2025), held in Zotero as N4GX98NZ with PDF attachment XLZFIVBS. It brings together the transfusion chapters from the 2025 fifth edition of the TDT Guidelines, the third NTDT Guidelines, and the alpha-thalassaemia guidance. Page locators below use the printed pages in that booklet. Every item in the bibliography was title-matched to its live source record during this review; DOI metadata was additionally matched against Crossref where a DOI exists.

</aside>

<aside> 🧭

The four decisions that make a transfusion plan safe

  1. Why now? Define the phenotype and present clinical problem.
  2. What regimen? Specify target, interval, dose and rate rather than copying a previous prescription.
  3. What unit? Match deliberately and preserve the antibody history.
  4. What has changed? Review benefit, iron, reactions, spleen, burden and the continuing indication. [1, pp. 5–25, 30–34, 38–43]

</aside>

Structured clinical pathway